SCHEMBL1998338

SCHEMBL1998338

O=C1CN(Cc2ccc(-c3cccc(CN4CCC(F)(F)CC4)c3)cc2)C(=O)N1CC1CCC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.40
BACE1 P56817 1/20 0.39
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38
ENPP2 Q13822 3/20 0.38
HRH3 Q9Y5N1 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRK1 P41145 1/20 0.35
OPRL1 P41146 1/20 0.35
GRIA2 P42262 1/20 0.35
ACHE P22303 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1998174 0.90 CYP2D6 (0.48) MCHR1ENPP2HRH3CYP2D6CYP2C19
SCHEMBL1997677 0.83 ENPP2 (0.39) MCHR1BACE1JAK2JAK1TYK2
SCHEMBL1998115 0.82 LMNA (0.41) MCHR1JAK2JAK1TYK2JAK3
SCHEMBL2002104 0.79 ENPP2 (0.43) ENPP2CYP2D6HDAC6
SCHEMBL1996322 0.78 CNR1 (0.44) MCHR1BACE1JAK2JAK1TYK2
SCHEMBL1998795 0.75 CYP2D6 (0.49) MCHR1ENPP2HRH3CYP2D6CYP2C19
SCHEMBL1997569 0.75 CYP2D6 (0.49) MCHR1ENPP2HRH3CYP2D6CYP2C19
SCHEMBL2002675 0.71 DHODH (0.43) JAK1ENPP2HRH3CYP2D6CYP2C19
SCHEMBL2000525 0.71 ENPP2 (0.52) MCHR1JAK2JAK1TYK2JAK3
SCHEMBL840558 0.71 HDAC6 (0.43) ENPP2OPRM1OPRL1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 MCHR1 663/4885BACE1 3568/4885JAK2 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.